Immunization by bovine thrombin used with fibrin glue during cardiovascular operations

Berruyer, Micheline; Amiral, Jean; Ffrench, Patrick; Belleville, J; Bastien, Olivier; Clerc, Jean; Kassir, Alain; Estanove, S; Dechavanne, M

doi:10.1016/s0022-5223(19)34162-5

Cited by 95 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As with the three cases described in this report, the most common contemporary cause of FV inhibitors has been exposure to bovine thrombin 46‐66 . Bovine thrombin is commonly mixed with fibrinogen derived from cryoprecipitate to make fibrin sealant, a hemostatic preparation used widely among the surgical specialties, particularly in cardiovascular surgery and neurosurgery 67 .…”

Section: Literature Review and Discussionmentioning

confidence: 81%

“…Although the vast majority of patients with FV inhibitors have been identified as a consequence of bleeding or coagulation laboratory abnormalities, occasional patients, paradoxically, have developed thrombosis 33,34,38,53,60,61,77 . However, because most of these patients had additional risk factors for thrombosis, it remains unclear whether these events can be attributed to the presence of the FV inhibitor 33,34,38,53,60,61,77 . Nevertheless, these cases serve as a useful reminder that despite causing markedly prolonged clotting times in vitro, FV inhibitors do not invariably protect patients from developing a thrombosis.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure

2002

View full text Add to dashboard Cite

show abstract

Section: Literature Review and Discussionmentioning

confidence: 81%

Section: Literature Review and Discussionmentioning

confidence: 99%

Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure

2002

View full text Add to dashboard Cite

show abstract

“…68 patients have been reported to have developed antibodies after surgical use of bovine thrombin alone (topical application) or as a component of fibrin sealant products [10]. In Europe, three cardiovascular surgical patients [11] developed antibodies to bovine thrombin and factor V shortly after exposure to a fibrin sealant, leading to decreased factor V activity. Similarly, 1 postoperative cardiovascular surgical patient followed up in Switzerland developed, after reexposure to fibrin sealant, antibodies to bovine thrombin and factor V, inducing severe factor V deficiency [12].…”

Section: Historical Perspectivementioning

confidence: 99%

Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use

Radosevich¹,

Goubran²,

Burnouf³

1997

Vox Sanguinis

191

127

View full text Add to dashboard Cite

Fibrin sealant is a complex plasma-derived product which is increasingly used as a biodegradable tissue adhesive or sealant to stop or control bleeding or provide air and fluid tightness in many surgical situations. This review describes the historical development of current fibrin sealant preparations and the scientific rationale behind the alleged physiological benefits of its major plasma-derived components. A comparison in the extraction methods and viral reduction treatments applied to current commercial products and autologous preparations, and their respective advantages and limits, are discussed. Application devices used for surgical applications are described. A survey of the major clinical applications in various surgical areas is presented. Current issues in terms of viral safety, definition of optimal fibrin sealant composition, and regulatory concerns, especially to demonstrate clinical efficacy, are also included.

show abstract

“…Until recently, the thrombin used to clot single‐donor FS was from bovine source. Bovine thrombin carries risks of inducing immunological reactions (formation of cross‐reactive anti‐FV or anti‐thrombin antibodies) in patients [16–21]. In addition, concerns over transmission of bovine infectious agents (such as bovine spongiform encephalopathy, the cause of variant Creutzfeldt‐Jakob disease in humans [22]) have been raised.…”

Section: Fibrin Sealantmentioning

confidence: 99%

Blood‐derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue

Burnouf

Radosevich

et al. 2009

ISBT Science Series

View full text Add to dashboard Cite

Blood‐derived biomaterials include fibrin sealant (FS) (also called fibrin glue), platelet gel (PG), and platelet fibrin glue. They are used in many surgical fields because of their functional properties and unique physical advantages compared to synthetic products. FS can be made industrially by the fractionation of large plasma pools, or from single plasma donations. Thanks to a high content in fibrinogen, FS exhibits, after activation by thrombin and formation of a strong fibrin clot, tissue sealing and haemostatic properties. PG and platelet fibrin glue are made from single blood donations (platelet concentrates combined or not with cryoprecipitate). Owing to their richness in platelet, PG and PFG can release, upon thrombin activation, a myriad of growth factors that can stimulate cell growth and differentiation, generating much interest for hard and soft tissues regeneration and healing, as well as, increasingly, cell therapy protocols to replace fetal bovine serum. Blood‐derived biomaterials have the advantages, over synthetic glues and other biomaterials, of being physiologically compatible with human tissues, and of not inducing tissue necrosis or other tissue reactions. They can be readily colonized by cells and are totally biodegradable in a matter of days to weeks. These blood‐derived biomaterials are used increasingly as tissue engineering tools, allowing surgeons to influence and improve the in vitro or in vivo cellular environment to enhance the success of tissue grafting. We review here the three main types of biomaterials that can be made from human blood and describe their biochemical and physiological properties as well as their clinical applications.

show abstract

Immunization by bovine thrombin used with fibrin glue during cardiovascular operations

Cited by 95 publications

References 15 publications

Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure

Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure

Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use

Blood‐derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue

Contact Info

Product

Resources

About